Assess Design Transfer and Production Readiness

Design transfer is frequently underestimated. Teams sometimes treat it as the moment drawings and a bill of materials are handed to a manufacturer. In reality, successful transfer requires translating design outputs into controlled production specifications that can be understood, executed, inspected, and maintained consistently.

A technically complete design package may include approved drawings, specifications, bills of materials, assembly procedures, inspection instructions, test methods, labeling requirements, packaging specifications, software configuration information, risk controls, approved suppliers, and acceptance criteria.

Missing or ambiguous information creates downstream risk. If a drawing does not define a critical tolerance, the manufacturer may make an assumption. If an inspection method is unclear, different operators may interpret it differently. If supplier substitutions are not controlled, a seemingly equivalent component may change product performance, biocompatibility, sterilization compatibility, or shelf life.

Before production begins, the manufacturer should conduct a structured review of the design package. The purpose is not merely to identify whether files are present. It is to determine whether the information is sufficiently complete and internally consistent to support repeatable manufacturing.

This review can uncover unresolved tolerances, unavailable components, incomplete inspection criteria, impractical assembly steps, undefined cosmetic standards, packaging gaps, or test methods that are not suitable for production use. Addressing these issues before a formal build is far less expensive than discovering them after verification testing or clinical units have been produced.

Pathway supports medical device companies by connecting design and engineering decisions with quality, regulatory, packaging, and manufacturing considerations. This integrated approach can be particularly valuable when a device is not fully production-ready and requires structured engineering work before routine manufacturing can begin.

Confirm Experience With Verification and Validation Builds

Design verification and validation builds demand a higher level of control than ordinary prototypes. The units may support formal testing, packaging studies, sterilization validation, biocompatibility activities, usability work, clinical evaluation, or regulatory submissions.

The manufacturer should understand how the intended use of the units affects the build strategy. It should be clear whether units must be production-equivalent, production-intent, or manufactured using a justified representative process. Materials, components, equipment, operators, work instructions, inspections, and deviations should be controlled at a level appropriate to the purpose of the build.

Traceability is especially important. If a test fails, the team must be able to determine which materials, processes, equipment, and inspections were associated with the affected units. Without reliable records, it can be difficult to distinguish a design deficiency from a manufacturing anomaly or test-method problem.

Common mistakes include starting the build before the design is sufficiently stable, using unapproved components without documenting the rationale, making undocumented process adjustments, or producing units before test protocols and sample requirements have been finalized.

These shortcuts can undermine the usefulness of the resulting data. A build may appear to save time initially, only to create questions about whether the tested units accurately represented the intended device.

Pathway is structured to support device verification and early new product introduction manufacturing, including production-intent builds, process refinement, controlled documentation, packaging support, and preparation for future scale.

Include Packaging and Sterilization Early

Packaging should not be treated as a final purchasing task for sterile or shelf-life-sensitive medical devices. The packaging system must protect the device through manufacturing, sterilization, transportation, storage, and handling while maintaining the required barrier and product integrity.

Packaging decisions can influence sterilization compatibility, labeling space, shipping configuration, aging studies, distribution testing, seal-process validation, and the overall regulatory timeline. A late packaging change may require additional testing or repeat validation work, potentially delaying a submission or launch.

For sterile devices, the package and sterilization process must be developed as connected systems. Materials must tolerate the selected sterilization modality. Package seals must remain intact after processing and distribution. The device must be presented safely and appropriately in the clinical environment.

ISO 11607 is widely used as the foundational standard for terminally sterilized medical device packaging. It addresses packaging-system requirements and the validation of forming, sealing, and assembly processes. A qualified contract manufacturer should understand how packaging development, sealing parameters, equipment qualification, distribution simulation, accelerated aging, and sterile-barrier testing fit into the broader commercialization plan.

The manufacturer does not necessarily need to perform every sterilization or laboratory activity internally. It should, however, be able to coordinate qualified providers, maintain traceability, prepare samples correctly, and integrate the resulting documentation into the program.

Pathway provides medical device packaging development, testing, validation, sealing, sourcing, and sterilization coordination as part of its broader development and manufacturing support.

Determine Whether Cleanroom Manufacturing Is Required

Not every medical device requires cleanroom assembly, but environmental requirements should be assessed early. Devices may require controlled manufacturing environments because of particulate, bioburden, sterility, surface cleanliness, optical performance, adhesive sensitivity, or product-specific risk controls.

A manufacturer should be able to explain the classification and monitoring of its controlled environments, the activities permitted within them, its cleaning procedures, gowning controls, material flow, environmental monitoring, and how excursions are investigated.

Simply stating that a facility has a cleanroom does not provide enough information. Companies should determine whether the room classification, layout, equipment, operating controls, and available space are appropriate for the device and process.

The review should also consider whether incoming materials require cleaning, whether assembly fixtures can be introduced into the room, how finished units are transferred to packaging, and how the manufacturer prevents mix-ups or cross-contamination among programs.

Pathway offers GMP and ISO-controlled cleanroom manufacturing for medical device assembly, pilot builds, validation lots, packaging, and production-readiness activities. Its approach is designed to support both immediate build requirements and eventual transfer to larger-scale production when appropriate.

Understand Capacity, Scalability, and Transfer Strategy

Companies often ask whether a contract manufacturer can produce a particular annual volume. That question matters, but it should be considered alongside development needs, forecast reliability, tooling requirements, labor capacity, equipment availability, and the expected rate of growth.

A manufacturer that is optimized for millions of units may not provide sufficient flexibility during development. Conversely, a development-focused manufacturer may not be intended to remain the final production site once demand reaches a much larger scale.

This is not necessarily a disadvantage. The correct partner is the one aligned with the program’s current risk profile and operational needs.

For many emerging medical device companies, the most effective strategy is to work with a manufacturer that can support engineering builds, verification, validation, clinical production, pilot manufacturing, and early commercialization while developing processes that can later be transferred to a larger facility.

A transfer-ready strategy requires disciplined documentation from the beginning. Fixtures, process parameters, work instructions, inspection methods, equipment requirements, supplier information, validation records, and lessons learned should be captured in a form that another qualified organization can reproduce.

When interviewing manufacturers, discuss not only present capacity but also the expected transition plan. Ask what happens if demand grows faster than anticipated, which operations can be automated, what additional equipment would be required, and how the manufacturer would support a future transfer.

Consider the Value of a San Diego Manufacturing Partner

San Diego offers a dense network of biotechnology, diagnostics, medical device, research, clinical, engineering, and manufacturing organizations. For local medtech companies, proximity to a contract manufacturer can provide practical advantages throughout development and commercialization.

Engineering and manufacturing teams can meet in person to review fixtures, observe assembly processes, investigate failures, approve first articles, and resolve design questions. Physical access is particularly useful during early builds, when drawings and specifications may not capture every aspect of the device.

Local collaboration can also shorten communication cycles. Instead of shipping components across the country for every review or relying exclusively on video calls, teams can visit the manufacturing floor and evaluate issues directly.

The benefit is not simply convenience. Faster technical feedback can reduce the time between identifying a problem and implementing a controlled solution. This becomes especially valuable when the program is approaching a verification build, clinical milestone, submission deadline, or investor commitment.

Local manufacturing may also improve oversight. Device companies remain responsible for evaluating and controlling suppliers, and accessible facilities can make audits, build observations, and periodic business reviews more practical.

San Diego should not be the only criterion, however. A nearby manufacturer is valuable only if it also possesses the appropriate quality system, technical competencies, facilities, documentation practices, and program fit.